EMPLOYMENT AGREEMENTEmployment Agreement • March 27th, 2012 • NovaBay Pharmaceuticals, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 27th, 2012 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of March 26, 2012 by and between NovaBay Pharmaceuticals, Inc. (“Company”) and Behzad Khosrovi (“Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 27th, 2012 • NovaBay Pharmaceuticals, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 27th, 2012 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of March 26, 2012 by and between NovaBay Pharmaceuticals, Inc. (“Company”) and Thomas J. Paulson (“Executive”).
CONFIDENTIAL TREATMENT REQUESTED BY NOVABAY PHARMACEUTICALS, INC. INTERNATIONAL DISTRIBUTION AGREEMENTInternational Distribution Agreement • March 27th, 2012 • NovaBay Pharmaceuticals, Inc. • Pharmaceutical preparations • Hong Kong
Contract Type FiledMarch 27th, 2012 Company Industry JurisdictionThis International Distribution Agreement (the “Agreement”) is effective as of the 9th day of January, 2012 (the “Effective Date”) by and between Pioneer Pharma Co. Ltd., with its principal place of business at Suite A-C 18F, HuDong Finance Building, No.1128, XiangYin Road, Shanghai, P.R.C. (“Pioneer”) and NovaBay Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 5980 Horton Street, Suite 550, Emeryville, CA 94608 (“NBY”), for the purpose of defining the rights and duties of the parties in connection with the distribution and potential development by Pioneer of NBY’s certain proprietary drug product.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 27th, 2012 • NovaBay Pharmaceuticals, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 27th, 2012 Company Industry JurisdictionTHIS EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of March 26, 2012 by and between NovaBay Pharmaceuticals, Inc. (“Company”) and Roy J. Wu (“Executive”).